Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
32,500
Employees32,500
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
32,500
Employees32,500

BMY Key Statistics

Market cap
118.39B
Market cap118.39B
Price-Earnings ratio
15.92
Price-Earnings ratio15.92
Dividend yield
4.41%
Dividend yield4.41%
Average volume
13.58M
Average volume13.58M
High today
$58.49
High today$58.49
Low today
$57.16
Low today$57.16
Open price
$57.79
Open price$57.79
Volume
10.05M
Volume10.05M
52 Week high
$62.89
52 Week high$62.89
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

As of today, Bristol-Myers Squibb(BMY) shares are valued at $58.09. The company's market cap stands at 118.39B, with a P/E ratio of 15.92 and a dividend yield of 4.41%.

On 2026-07-08, Bristol-Myers Squibb(BMY) stock traded between a low of $57.16 and a high of $58.49. Shares are currently priced at $58.09, which is +1.6% above the low and -0.7% below the high.

Bristol-Myers Squibb(BMY) shares are trading with a volume of 10.05M, against a daily average of 13.58M.

In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $62.89 and a 52-week low of $42.52.

In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $62.89 and a 52-week low of $42.52.

BMY News

MarketWatch 1d
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch

...

Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Nasdaq 5d
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug

Roche RHHBY reported positive results from the late-stage Krascendo 1 study evaluating experimental candidate, divarasib, in patients with previously treated KR...

Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
Simply Wall St 5d
BMY’s Shift Into Russell Value Defensive Indexes Might Change The Case For Investing In Bristol-Myers Squibb

In late June 2026, Bristol-Myers Squibb was removed from several Russell growth benchmarks and simultaneously added to the Russell 1000 Value Defensive and Russ...

BMY’s Shift Into Russell Value Defensive Indexes Might Change The Case For Investing In Bristol-Myers Squibb

Analyst ratings

60%

of 30 ratings
Buy
36.7%
Hold
60%
Sell
3.3%

More BMY News

Simply Wall St 6d
Bristol Myers Squibb Joins Defensive Value Indexes, Is It Still 8% Undervalued?

Bristol-Myers Squibb (BMY) is being reclassified across key Russell indexes, exiting several growth benchmarks and entering the Russell 1000 Defensive and Russe...

Bristol Myers Squibb Joins Defensive Value Indexes, Is It Still 8% Undervalued?

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.